Tonix Pharmaceuticals Holding (TNXP) Common Equity (2010 - 2026)

Tonix Pharmaceuticals Holding has reported Common Equity for 17 years, with the latest figure at $222.3 million in Q2 2026.

• On a quarterly basis, Common Equity rose 32.31% year-over-year to $222.3 million in Q2 2026; TTM through Jun 2026 was $222.3 million, a 32.31% increase from a year earlier, with the FY2025 full-year figure at $245.2 million, up 75.66% from the prior year.
• Common Equity was $222.3 million for Q2 2026 at Tonix Pharmaceuticals Holding, down from $227.1 million in the prior quarter.
• The five-year high for Common Equity was $245.2 million in Q4 2025, with the low at $42.1 million in Q2 2024.
• Average Common Equity over 5 years is $169.0 million, with a median of $174.2 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2025: Common Equity tumbled 70.03% in 2024, then soared 299.02% in 2025.
• Over 5 years, Common Equity stood at $207.2 million in 2022, then tumbled by 49.07% to $105.5 million in 2023, then jumped by 32.25% to $139.6 million in 2024, then surged by 75.66% to $245.2 million in 2025, then retreated by 9.33% to $222.3 million in 2026.
• The last three Common Equity figures came in at $222.3 million (Q2 2026), $227.1 million (Q1 2026), and $245.2 million (Q4 2025), per Business Quant data.